New data show risk-based and centralized monitoring shifts effort across roles, sites, and timelines, reshaping how sponsors plan CRA capacity needs.
News|Articles|October 28, 2024
AI-Driven Label-Free Quantification of Cell Viability Using Live-Cell Analysis
Author(s)Sartorius
Live-cell imaging enables acquisition of phase contrast images and provides an ideal platform to study multi-faceted biological paradigms in drug discovery. This is vital to our understanding of human diseases and treatment strategies. The movement of these models towards increasingly complex physiologically relevant ones, including patient-derived cells and induced pluripotent stem cells (iPSCs), has concurrently driven the need for label-free methods that are non-perturbing to deliver deeper biological insights.
Related to this article
Laru-zova helped 31% of high-dose patients gain 15+ letters of vision, representing the first pivotal trial to succeed in treating XLRP.
Telix will acquire ITM for $1.65 billion, gaining a phase 3-validated therapy that cut GEP-NET progression risk versus everolimus.
mAbxience and Sandoz are targeting a $5.7 billion market with a proposed emicizumab biosimilar for hemophilia A.
Fayuvi scored 23.5 points higher than untreated peers on cognitive testing, backing the first-ever approval for a Sanfilippo syndrome A gene therapy.
Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
FDA compliance officers detailed 2026 guidance updates, online drug sale enforcement, and a first-of-its-kind AI-related warning letter at the PDA/FDA Joint Regulatory Conference.
Sanofi’s Jack Prior discusses how biopharmaceutical manufacturers can assess whether process data is ready for human and AI use, and the role of data quality, accessibility, governance, and AI in manufacturing.